Post by Tinnitus on Jun 17, 2020 20:21:40 GMT 1
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
--
Shares of Biogen fell 6.5% in April as the company announced that it would complete its Food and Drug Administration filings for its controversial Alzheimer's disease drug later than it had previously indicated.
--
No debt, great ROIC, stellar operating margins, and operating income of over 7bn. They are projected to grow EPS between 8-16% in future years based on weighted average growth in the last 4 years. This is easily worth northward of 400USD per share even without expected growth.
--
Volume from recent months suggest an entry price of around 276 (which I recently bought at) and a target price of 341
--
Shares of Biogen fell 6.5% in April as the company announced that it would complete its Food and Drug Administration filings for its controversial Alzheimer's disease drug later than it had previously indicated.
--
No debt, great ROIC, stellar operating margins, and operating income of over 7bn. They are projected to grow EPS between 8-16% in future years based on weighted average growth in the last 4 years. This is easily worth northward of 400USD per share even without expected growth.
--
Volume from recent months suggest an entry price of around 276 (which I recently bought at) and a target price of 341